1073 related articles for article (PubMed ID: 22832583)
21. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.
Kool M; Koster J; Bunt J; Hasselt NE; Lakeman A; van Sluis P; Troost D; Meeteren NS; Caron HN; Cloos J; Mrsić A; Ylstra B; Grajkowska W; Hartmann W; Pietsch T; Ellison D; Clifford SC; Versteeg R
PLoS One; 2008 Aug; 3(8):e3088. PubMed ID: 18769486
[TBL] [Abstract][Full Text] [Related]
22. PTCH1-mutant human cerebellar organoids exhibit altered neural development and recapitulate early medulloblastoma tumorigenesis.
van Essen MJ; Apsley EJ; Riepsaame J; Xu R; Northcott PA; Cowley SA; Jacob J; Becker EBE
Dis Model Mech; 2024 Feb; 17(2):. PubMed ID: 38411252
[TBL] [Abstract][Full Text] [Related]
23. Medulloblastoma: Molecular Classification-Based Personal Therapeutics.
Archer TC; Mahoney EL; Pomeroy SL
Neurotherapeutics; 2017 Apr; 14(2):265-273. PubMed ID: 28386677
[TBL] [Abstract][Full Text] [Related]
24. Pik3ca mutations significantly enhance the growth of SHH medulloblastoma and lead to metastatic tumour growth in a novel mouse model.
Niesen J; Ohli J; Sedlacik J; Dührsen L; Hellwig M; Spohn M; Holsten T; Schüller U
Cancer Lett; 2020 May; 477():10-18. PubMed ID: 32112900
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Clinical and Molecular Wnt and SHH Subgroups in Medulloblastoma Tumor Cases.
Kaya IS; Aksoy S; Mutlu M; Tekin C; Taskapilioglu MO; Tunca B; Civan MN; Ocak PE; Kocaeli H; Bekar A; Egeli U; Cecener G; Tolunay S
Turk Neurosurg; 2021; 31(4):554-565. PubMed ID: 33978203
[TBL] [Abstract][Full Text] [Related]
26. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression.
Thomas WD; Chen J; Gao YR; Cheung B; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B; Marshall GM
Oncogene; 2009 Apr; 28(13):1605-15. PubMed ID: 19234491
[TBL] [Abstract][Full Text] [Related]
27. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
[TBL] [Abstract][Full Text] [Related]
28. Contrast enhancement pattern predicts poor survival for patients with non-WNT/SHH medulloblastoma tumours.
Łastowska M; Jurkiewicz E; Trubicka J; Daszkiewicz P; Drogosiewicz M; Malczyk K; Grajkowska W; Matyja E; Cukrowska B; Pronicki M; Perek-Polnik M; Perek D; Dembowska-Bagińska B
J Neurooncol; 2015 May; 123(1):65-73. PubMed ID: 25862008
[TBL] [Abstract][Full Text] [Related]
29. Medulloblastomics: the end of the beginning.
Northcott PA; Jones DT; Kool M; Robinson GW; Gilbertson RJ; Cho YJ; Pomeroy SL; Korshunov A; Lichter P; Taylor MD; Pfister SM
Nat Rev Cancer; 2012 Dec; 12(12):818-34. PubMed ID: 23175120
[TBL] [Abstract][Full Text] [Related]
30. Simplified Molecular Subtyping of Medulloblastoma for Reduced Cost and Improved Turnaround Time.
Shuangshoti S; Tadadontip P; Techavichit P; Thorner PS; Shuangshoti S; Teerapakpinyo C
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):538-543. PubMed ID: 31343993
[TBL] [Abstract][Full Text] [Related]
31. Upregulation of the chromatin remodeler HELLS is mediated by YAP1 in Sonic Hedgehog Medulloblastoma.
Robinson MH; Maximov V; Lallani S; Farooq H; Taylor MD; Read RD; Kenney AM
Sci Rep; 2019 Sep; 9(1):13611. PubMed ID: 31541170
[TBL] [Abstract][Full Text] [Related]
32. Subgroup and subtype-specific outcomes in adult medulloblastoma.
Coltin H; Sundaresan L; Smith KS; Skowron P; Massimi L; Eberhart CG; Schreck KC; Gupta N; Weiss WA; Tirapelli D; Carlotti C; Li KKW; Ryzhova M; Golanov A; Zheludkova O; Absalyamova O; Okonechnikov K; Stichel D; von Deimling A; Giannini C; Raskin S; Van Meir EG; Chan JA; Fults D; Chambless LB; Kim SK; Vasiljevic A; Faure-Conter C; Vibhakar R; Jung S; Leary S; Mora J; McLendon RE; Pollack IF; Hauser P; Grajkowska WA; Rubin JB; van Veelen MC; French PJ; Kros JM; Liau LM; Pfister SM; Kool M; Kijima N; Taylor MD; Packer RJ; Northcott PA; Korshunov A; Ramaswamy V
Acta Neuropathol; 2021 Nov; 142(5):859-871. PubMed ID: 34409497
[TBL] [Abstract][Full Text] [Related]
33. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
Ramaswamy V; Remke M; Bouffet E; Faria CC; Perreault S; Cho YJ; Shih DJ; Luu B; Dubuc AM; Northcott PA; Schüller U; Gururangan S; McLendon R; Bigner D; Fouladi M; Ligon KL; Pomeroy SL; Dunn S; Triscott J; Jabado N; Fontebasso A; Jones DT; Kool M; Karajannis MA; Gardner SL; Zagzag D; Nunes S; Pimentel J; Mora J; Lipp E; Walter AW; Ryzhova M; Zheludkova O; Kumirova E; Alshami J; Croul SE; Rutka JT; Hawkins C; Tabori U; Codispoti KE; Packer RJ; Pfister SM; Korshunov A; Taylor MD
Lancet Oncol; 2013 Nov; 14(12):1200-7. PubMed ID: 24140199
[TBL] [Abstract][Full Text] [Related]
34. Serpine2/PN-1 Is Required for Proliferative Expansion of Pre-Neoplastic Lesions and Malignant Progression to Medulloblastoma.
Vaillant C; Valdivieso P; Nuciforo S; Kool M; Schwarzentruber-Schauerte A; Méreau H; Cabuy E; Lobrinus JA; Pfister S; Zuniga A; Frank S; Zeller R
PLoS One; 2015; 10(4):e0124870. PubMed ID: 25901736
[TBL] [Abstract][Full Text] [Related]
35. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
Gajjar A; Robinson GW; Smith KS; Lin T; Merchant TE; Chintagumpala M; Mahajan A; Su J; Bouffet E; Bartels U; Schechter T; Hassall T; Robertson T; Nicholls W; Gururangan S; Schroeder K; Sullivan M; Wheeler G; Hansford JR; Kellie SJ; McCowage G; Cohn R; Fisher MJ; Krasin MJ; Stewart CF; Broniscer A; Buchhalter I; Tatevossian RG; Orr BA; Neale G; Klimo P; Boop F; Srinivasan A; Pfister SM; Gilbertson RJ; Onar-Thomas A; Ellison DW; Northcott PA
J Clin Oncol; 2021 Mar; 39(7):822-835. PubMed ID: 33405951
[TBL] [Abstract][Full Text] [Related]
36. Transcriptional up-regulation of Gadd45a in Patched-associated medulloblastoma.
Kappler R; Hess I; Schlegel J; Hahn H
Int J Oncol; 2004 Jul; 25(1):113-20. PubMed ID: 15201996
[TBL] [Abstract][Full Text] [Related]
37. Medulloblastoma molecular dissection: the way toward targeted therapy.
Remke M; Ramaswamy V; Taylor MD
Curr Opin Oncol; 2013 Nov; 25(6):674-81. PubMed ID: 24076581
[TBL] [Abstract][Full Text] [Related]
38. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
[TBL] [Abstract][Full Text] [Related]
39. Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.
Sursal T; Ronecker JS; Dicpinigaitis AJ; Mohan AL; Tobias ME; Gandhi CD; Jhanwar-Uniyal M
Anticancer Res; 2022 May; 42(5):2225-2239. PubMed ID: 35489737
[TBL] [Abstract][Full Text] [Related]
40. Methylation of PTCH1, the Patched-1 gene, in a panel of primary medulloblastomas.
Pritchard JI; Olson JM
Cancer Genet Cytogenet; 2008 Jan; 180(1):47-50. PubMed ID: 18068533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
